Method for treating inflammatory diseases

一种发炎性疾病、疾病的技术，应用在心血管系统疾病、抗炎剂、医药配方等方向，能够解决心血管疾病结果不一致等问题，达到高度生物兼容性的效果

Inactive Publication Date: 2020-09-01
叶宏一 +1
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Non-steroidal anti-inflammatory drugs are widely used clinically to reduce atherosclerosis. However, the results of this drug in the treatment of cardiovascular diseases are not consistent, let alone the many side effects reported in recent years

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treating inflammatory diseases
  • Method for treating inflammatory diseases
  • Method for treating inflammatory diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0068] Materials and Methods

[0069] Synthesis of DHLA-coated gold nanoclusters (FANC) and preparation of cultured cells

[0070] Human aortic endothelial cells (hereinafter referred to as HAEC) were cultured in endothelial cell growth containing 5% fetal bovine serum (FBS) and endothelial cell growth supplement (hereinafter referred to as complete medium; purchased from PromoCell, Heidelberg, Germany) Medium (MV). at 37°C with 5% CO 2 HAEC were cultured in complete medium in a humidified incubator with / 95% air and subcultured twice a week. The DHLA-coated gold nanoclusters used in this experiment were prepared based on precursor-induced etching of gold (Au) nanoparticles (NPs) (Lin et al., ACS Nano, 2009, 3(2), pp 395– 401). Briefly, first in toluene (tolune) by dissolving 0.8 ml of gold precursor (AuCl 3 , 7.5 mg / ml) was added to 1 ml of freshly prepared tetrabutylammonium borohydride (tetrabutylammonium borohydride, TBAB) (100 mmol / L DDAB solution) and 0.675 ml capri...

experiment example 1

[0090] Experimental example 1: Effect of clathrin-mediated endocytosis on FANC internalization

[0091] After 45 minutes of inhibitor pretreatment (except for filipin which was treated for 30 minutes), FANC was added and incubation was continued for an additional 80 minutes. Next, the cells are passed through a flow cytometer. Figure 1A –1D). In complete medium, chlorpromazine hydrochloride and amiloride, which inhibit clathrin-dependent endocytosis and macropinocytosis, respectively, and inhibition of clathrin-non-clathrin endocytosis with minor effects on FANC internalization Agents (including genistein and filipin) ( Figure 1A ). However, in serum or serum-free medium, FANC internalization was blocked by chlorpromazine hydrochloride (compared to FANC control group, 1% FBS medium decreased by 60%, and serum-free medium decreased by 51%; Figure 1B and Figure 1C ). Confocal microscopy showed that chlorpromazine hydrochloride treatment could down-regulate the punctate...

experiment example 2

[0092] Experimental Example 2: Beneficial Effect of FANC on Inflammatory Response in Vitro

[0093] To examine cell markers that can be affected by FANC, cells maintained in complete medium supplemented with FANC were cultured for up to four weeks and assessed by real-time PCR at specific time points (days 21 and 28) . Transcripts of endothelial activity involved in angiogenesis, inflammation, coagulation, adhesion, growth, and vasodilation were examined. The results showed that the down-regulation of growth factors, adhesion molecules and coagulation factors was in a dose-dependent manner ( Figure 2A and Figure 2B ). It can be observed that compared with the control group (without FANC treatment), after 21 days of culture with FANC supplement (150nmol / L), the reduced molecules are VEGF, 88%; ICAM-1 (the diagram is ICAM): 64%; VCAM-1 (VCAM pictured): 74%; P-selectin: 88%; PAI-1: 64%; and vWF: 75% (Figure 2A; *: P Figure 2B ;*: P<0.05). In contrast, FANC had only minimal...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed herein is a method for treating an inflammatory disease in a subject, including administering to the subject a therapeutically effective amount of a dihydrolipoic acid (DHLA) coated gold nanocluster about 0.1 to 20 nm in diameter. Also disclosed is a method for reducing the expression of a pro-inflammatory molecule in a cultured cell, including contacting the cultured cell with the saidDHLA coated gold nanocluster. Still disclosed is a pharmaceutical composition that includes the present DHLA coated gold nanocluster. The pharmaceutical composition is useful for treating the inflammatory disease in the subject.

Description

【Technical field】 [0001] Cross-reference to related application [0002] This application claims priority from U.S. Patent Provisional Application No. 62 / 809,762 filed on February 25, 2019, the entire contents of which are incorporated in part of the patent specification of this application by reference. [0003] The present disclosure is in the related field of treating inflammatory diseases. Specifically, the disclosure relates to a method for treating inflammatory diseases by coating gold nanoclusters with dihydrolipoic acid (DHLA), which can downregulate the expression levels of inflammation-related factors . 【Background technique】 [0004] Cardiovascular disease (CCD) is a general term for several associated pathologies involving the heart or blood vessels, and is the leading cause of death worldwide. Atherosclerosis (atherosclerosis) is the disease that forms when plaque builds up on the artery wall, which is the underlying mechanism of certain cardiovascular diseas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K33/242A61K31/20A61P29/00
CPCA61K33/242A61K31/20A61P29/00A61K2300/00A61K31/385A61K45/06A61P9/00A61K31/352A61K31/365A61K31/4965A61K31/5415A61K33/24A61K9/5115A61K9/0019A61K9/5123
Inventor 王学孝叶宏一张恒雄
Owner 叶宏一
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap